Material Detail
Eli Lilly: Recreating Drug Discovery for the 21st Century
This case "describes changes facing the structure of the pharmaceutical industry as a result of new science and untenable cost structures and Eli Lilly's long-range strategy involving the development of tailored drugs." The case is a "follow on case to 'Lillys Project Resilience,' although it can also be taught as a stand alone case. Designed to explore the issues inherent in trying to implement a significantly different strategy without investing in significant organizational change. Explores the choices Lilly has made to invest in 'tailored therapeutics' and asks the students to consider whether they will lead to success."
Quality
-
Peer Review
-
User Rating
- Comments
- Learning Exercises
- Bookmark Collections
- Course ePortfolios
- Accessibility Info
More about this material
- Material Type:
- Case Study
- Date Added to MERLOT:
- January 27, 2009
- Date Modified in MERLOT:
- October 2, 2022
- Author:
- Rebecca Henderson, MIT Sloan School of Management
- Submitter:
-
Cathy Swift
- Primary Audience:
- College Upper Division, Graduate School, Professional
- Technical Format:
- Mobile Compatibility:
- Not specified at this time
- Language:
- English
- Cost Involved:
- No
- Source Code Available:
- Unknown
- Creative Commons:
-
This work is licensed under a Attribution-NonCommercial-ShareAlike 3.0 United States
